Robert Marcus
JPMorgan Chase & Co, Analysis Division
Good morning, everybody. I am Robbie Marcus, med tech analyst at JPMorgan. Actually comfortable to introduce our subsequent speaker, CEO of Zimmer Biomet, Ivan Tornos. He’ll do a presentation adopted by some Q&A. Ivan.
Ivan Tornos
President, CEO & Chairman of the Board
Thanks. So good morning. The morning already began in an attention-grabbing method as a result of I used to be getting my microphone on, and I used to be speaking to Cesar, the man in command of IT and instantly detected the accent. Requested me the place I am from, I see Madrid, and he proceed to speak to me about how Barcelona beat Actual Madrid over the weekend. So at this level, every little thing has to go uphill.
Look, I do know that this can be a busy week. I do know that within the subsequent 3 to 4 days, all of you most likely can pay consideration or will attempt to concentrate to at least 40 or 50 shows. So I’ll attempt to summarize my whole presentation within the first minute, after which we’ll undergo the slides in, as an example, 10, quarter-hour, after which a very powerful half, I would wish to get going with the Q&A. And hopefully, we’ll get some questions from the viewers as effectively.
So every little thing that you must find out about Zimmer Biomet in 2026, exhausting to consider we already are in 2026. Look, we’re more than happy, very inspired with the progress we made during the last 5 years. It was
